News

 

May 2019

 

April 2019

 

March 2019

  • The paper by Kashyap et al. « Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.» has been published in Journal for ImmunoTherapy of Cancer
 

February 2019

  • The paper by Trefny et al. « A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.» has been published in Clinical Cancer Research
 

January 2019

  • The paper by Alexandros Papachristofilou et al. «Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer» has been published in Journal for ImmunoTherapy of Cancer
  • The paper by D’Amico et al. «A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer» has been published in Journal for ImmunoTherapy of Cancer
 

December 2018

  • Dr. Michal Stanczak successfully defended his PhD thesis.
  • We had a very productive and enjoyable lab retreat in Reigoldswil (Wasserfallen). We thank our advisors, Prof. Georg Holländer and Prof. Daniel Speiser for the valuable comments and suggestions!
 

Oktober 2018

  • We welcome our new technician Florian Rosentreter to our lab
 

September 2018

  • The paper by Pearce et al. «Cancer Immunotherapy.» has been published in Glycobiology.
  • The paper by Sanchez et al. «Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.» has been published in J Immunother Cancer.
 

August 2018

  • We welcome our new postdoc Anne Bärenwaldt to the lab
  • The paper by Läubli et al. «Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.» has been published in Virchows Arch.
  • The paper by Stanczack et al. « Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.» has been published in J Clin Invest.
 

Juli 2018

  • Schweizer Familie” Ausgabe 29/2018
    Krebs bekämpfen mit Hilfe des Immunsystems
    Manche Krebsarten bedeuten für Betroffene bis vor kurzem ein Todesurteil. Nun lässt eine neue Therapie einen Teil der Patienten hoffen. Sie befähigt körpereigene Abwehrzellen, Tumoren zu erkennen und zu attackieren.
    Hier gehts zum Artikel
  • Immuntherapie gegen Krebs: Geplatzte Versprechen?
    Vor ein paar Jahren feierten Krebsmediziner die Immuntherapie als Hoffnungsträgerin. Patienten, die an besonders aggressiven Tumoren erkrankt waren, konnten damit geheilt werden. Doch der Hype hat Schattenseiten.
    Kritiker sagen: Medikamente würden zu schnell und zu unüberlegt auf den Markt geworfen, Chancen dadurch vertan.
    Hier gehts zum Beitrag
 

Juni 2018

  • The paper by Thommen et al. «A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.» has been published in Nature medicine.
  • Christine Huynh successfully defended her master thesis.
 

Mai 2018

  • The paper by Läubli et al. «Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.» has been published in Journal for ImmunoTherapy of Cancer.
 

April 2018

  • We had a very funny bowling event after our yearly big laboratory cleaning afternoon.
 

  • We welcome our new postdoc Elham Pishali to the lab.
  • We welcome our new technician Regina Dönen to the lab.
 

March 2018

  • We welcome our new PhD student Laura Fernandez Rodriguez to the lab
 

February 2018

  • The paper by Läubli et al. «The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.» has been published in Cancer Immunology
  • We welcome our new postdoc Yang Liu to the lab
  • We welcome our new postdoc Gianni Monaco to the lab
 

January 2018

  • The paper by Murekatete et al. « Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.» has been published in Scientific Reports.
  • We welcome our new postdoc Marta Trüb to the lab.
     

    December 2017

    • The review by Adams et al. « Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.» has been published in Glycobiology.
    • We had a very productive and enjoyable lab retreat in Reigoldswil (Wasserfallen). We thank our advisors, Prof. Pedro Romero and Prof. Ed Palmer, for the valuable comments and suggestions!
       

      October 2017

      • Dr. Vincent Prêtre successfully defended his PhD thesis.
      • Dr Lucia D’Amico received a grant from the KTI.
      • The paper by Läubli et al. « The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.» has been published in Onco Immunology.
       

      August 2017

      • We welcome our new master student Christine Huynh to the team.
       

      July 2017

      • Dr. Heinz Läubli received a grant from «Krebsliga Beider Basel» and «Swiss Cancer Research»
       

      • We warmly welcome our youngest member of the team, born July 2017, Mathilda Uhlenbrock. Congratulations to Franziska Uhlenbrock!
       

      June 2017

      • The paper by Läubli et al. «Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.» has been published in Journal for ImmunoTherapy of Cancer.
      • We welcome our new PhD student Natalia Rodrigues Mantuano to the team.
       

      May 2017

       

      April 2017

      • Dr. Abhishek Kashyap received a traveling grant for an abstract presentation at the Keystone Meeting in Whistler this year from Bio-Techne.
       

      March 2017

      • «HörPunkt» on Radio SRF 2: A look into the refrigerator with Franziska Uhlenbrock.
      • Dr. Heinz Läubli and Michal Stanczak had both an oral presentation at the Gordon Research Conference (GRC) for Glycobiology in Ventura, CA
       

      February 2017

      • Martin Thelen successfully defended his master thesis.
       

      January 2017

      • Dr. Daniela Thommen received a grant from the Sassella Stiftung.
      • We welcome our new technician Marina van Ark to the team.
       
      «Echo der Zeit» auf Radio SRF vom 7. Januar 2017

      Fortschritte in der Krebstherapie machen Hoffnung

      Lange Zeit waren Worte wie Durchbruch, Erfolg oder gar Heilung fast schon Tabu in der Krebsmedizin. Seit einiger Zeit hört man sie aber immer wieder. Allerdings ist es schwer abzuschätzen, wie vielen Patienten die neuen Therapiemöglichkeiten tatsächlich helfen.

       

      Zur Sendung

       

      December 2016

      • The SNF accepted a Sinergia project which involves a collaboration with Prof. Plückthun and Prof. Greber (both at the University of Zurich) and Prof. Zippelius (DBM, University of Basel).
      • Dr. Heinz Läubli received a personal research grant from the Goldschmidt-Jacobson Stiftung «Bed to Bench for Top Clinicians».
      • Dr. Franziska Uhlenbrock received a personal research grant from the University of Basel «Forschungsfond 2016 zur Förderung exzellenter Nachwuchsforschender».
       

      November 2016

      • Prof. Zippelius gave an invited lecture at the World Immunotherapy Congress/European antibody meeting in Basel.
      • Prof. Zippelius has been elected Vice-President of the Immuno-Oncology Working Group at SAKK.
      • Dr. Abhishek Kashyap received a grant from the Huggenberger-Bischoff Foundation.
       

      October 2016

      • Prof. Zippelius received a grant from the «Impulsinvestition für die Ausweitung der Kooperation zwischen dem Departement für Biosysteme der ETH Zürich (D-BSSE) und der Universität Basel» in collaboration with Prof. Sai Reddy, ETH Zurich.
       

      September 2016

      • A poster and a lightning talk have been presented at the All SystemsX.ch Day 2016 by Dr. Lucia’Damico.
      • We welcome our new master student Monika Kaiser to the lab.
      • We welcome our new postdoc Sandra Kallert to the lab.
       
      «NZZ am Sonntag» vom 18. September 2016

      Neue Therapien können das Leben von Menschen mit Krebs deutlich verlängern

      Wie Erfahrungen der letzten Jahre zeigen, erzielen die Medikamente der Immuntherapie verblüffende Resultate bei Krebsarten, die bis jetzt nur schwer zu behandeln waren. «Ich hatte Patienten, die kurz davor waren zu sterben und heute ein normales Leben führen», sagt Prof. Alfred Zippelius, stellvertretender Chefarzt Onkologie am Universitätsspital Basel.

      Zum Artikel

       

      August 2016

      • Dr. Abhishek Kashyap received an international traveling grant from the SNF.
       
      «Mediaplanet» vom 29. August 2016

      Krebs mit Immuntherapie bekämpfen

      Thema Immunonkologie: Prof. Alfred Zippelius, stv. Chefarzt Onkologie und Leiter Labor Tumorimmunologie, erklärt warum das Immunsystem ein sehr starkes Instrument zur Bekämpfung von Krebserkrankungen ist.

       

      Zum Video

       

      July 2016

      • The paper by Kashyap et al. «Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I-Induced Breast Cancer Cell Functions.» has been published in Molecular Cancer Therapeutics.
      • We welcome our new master student Martin Thelen to the lab.
      • Dr. Lucia D’Amico received a grant from the KLBB.
       

      June 2016

      • The paper by D’Amico et al. «C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.» has been published in Oncotarget.
       

      May 2016

      • We welcome our new PhD student Marcel Trefny to the lab.
       

      April 2016

      • Dr. Heinz Läubli received a personal research grant from the Lichtenstein-Stiftung.
      • Vincent Prètre presented a poster at the AAACR Annual Meeting 2016 in New Orleans. Title: Final results of the pharmacodynamic (PD) data of PQR309-001, a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors 
      • Dr. Daniela Thommen presented a poster at the ELCC 2016 in Geneva. Title: Highly exhausted PD-1hi T cell subsets in human NSCLC are co-defined by the predominant expression of distinct inhibitory receptors and correlate with clinical outcome

       
       
      «Neue Zürcher Zeitung» vom 22. April 2016

      Hoffnungsträger für die Krebstherapie

      Checkpoints in Immunzellen verhindern, dass die körpereigene Abwehr überschiesst. Was bei Infektionen sinnvoll ist, schwächt die Krebsbekämpfung. Doch gibt es Wege, die Kontrolleure auszuschalten. Von Erfolgen berichtet auch Prof. Alfred Zippelius, stellvertretender Chefarzt Onkologie am Universitätsspital Basel.

       

      Zum Artikel

       

      March 2016

       
      «Der Landbote» vom 9. März 2016

      Immuntherapien gewinnen im Kampf gegen Krebs an Bedeutung

      Krebs kann heute wirksam auch mittels einer Immuntherapie behandelt werden. Die Erfahrungen zeigen, dass damit vielen Patienten geholfen wird. Dazu ein Interview mit Prof. Alfred Zippelius, stellvertretender Chefarzt Onkologie am Universitätsspital Basel und Leiter des an die Klinik angeschlossenen Labors für Tumorimmunologie.

       

      Zum Artikel

       

      December 2015

      • Dr. Rothschild received the SAKK/RTF-CCR/Gateway Cancer Research Grant.

       

      November 2015

      • We welcome our new postdoc Dr. Lucia D'Amico to the lab.
      • The paper by Müller et al.«Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTA-4/PD-1 blockade» has been published in Science Translational Medicine.

       

      October 2015

      • We welcome our new postdoc Dr. Abhishek Kashyap to the lab.

       

      September 2015

      • Alfred Zippelius is the recipient of a project grant from Swiss National Science Foundation.
      • The paper by Uda et al. «Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity» has been published in the Journal of Enzyme Inhibition and Medical Chemistry. 
      • The paper by Martin et al. «Modulation of APC function and anti-tumor immunity by anti-cancer drugs» has been published in Frontiers in Immunology.
      • We welcome our new Master student Dominik Kierig to the lab.

       

      August 2015

      • The paper by Thommen et al "Progression of lung cancer is associated with increased dysfunction of T cells defined by co-expression of multiple inhibitory receptors" has been published in Cancer Immunology Research.

       

      June 2015

      • Dr. Kea Martin successfully defended her PhD thesis.
      • The paper by Xue et al "Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy" has been published in Journal of National Cancer Institute.

       

      May 2015

       
      «Tages-Anzeiger.ch» vom 31. Mai 2015

      150'000 Dollar für neue Krebsmedikamente

      Trotz aggressiver Tumore leben einige Patienten mit den neusten Krebsmitteln über Jahre weiter. Alfred Zippelius, stellvertretender Chefarzt Onkologie, spricht von einem Durchbruch.

       

      Zum Artikel

       

      April 2015

      • The paper by Läubli et al «Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma» has been published in Journal for Immunotherapy of Cancer.

       

      March 2015

      • We welcome our new postdoc Dr. Fransziska Uhlenbrock to the lab.
      • The paper by Uda et al «Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity» has been accepted and published in Jounal of Enzyme Inhibition and Medical Chemistry.

       

      Feburary 2015

      • The review article by Rothschild et al «Cancer immunology - development of novel anti-cancer therapies» has been accepted and published in Swiss Medical Weekly.
       
       
      «Mediaplanet» vom Februar 2015

      Kampf gegen Krebs - die Behandlungsmöglichkeiten

      Nahezu 40 000 Menschen leiden in der Schweiz an Krebs. Die Behandlungsmethoden variieren stark. Prof. Alfred Zippelius, Stellvertretender Chefarzt Onkologie, Universitätsspital Basel, erklärt die gängigsten Therapieansätze.

       

      Zum Artikel

       

      January 2015

      • The paper by Zippelius et al, «Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment» has been published in Cancer Immunology Research.
      • The paper by Wieckowski et al «Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma» has been published in Lung Cancer.
      • Dr. Philipp Müller is currently on sabbatical at the Scripps Research Institute in Florida, where he is performing cancer related research on next generation antibody therapeutics. 
      • We welcome our new postdoc Dr. Gongda Xue to the lab.

       
       
      «10vor10» auf TV SRF vom 27. Januar 2015

      Immuntherapie: Neue Wege in der Krebsforschung

      Die Pharmaindustrie setzt Hoffnung auf Krebsmedikamente, die auf einem andern Prinzip als der Chemotherapie basieren: Die sogenannte Immuntherapie stärkt die körpereigenen Abwehrkräfte gegen die Krebszellen. Erste Erfahrungen zeigen: diese Medikamente zeigen deutlich bessere Heilungschancen und geringere Nebenwirkungen.

      Mit Prof. Alfred Zippelius, Stv. Chefarzt Onkologie, Universitätsspital Basel.

       

      Zur Sendung

       

      December 2014

      • Dr. Daniela Thommen received a personal research grant from the Lichtenstein-Stiftung.

       

      November 2014

      • A SystemsX Transfer Project together with Prof. Sai Reddy / D-BSSE ETH Zurich and Dr. Grawunder / NBE Therapeutics has been approved.
      • An abstract (best abstract session) and two posters have been presented at the ESMO Symposium on Immuno-Oncology in Geneva by Dr. Daniela Thommen.